Stock Price Movement and Market Context
On 4 February 2026, GPT Healthcare Ltd opened with a gap down of -4.42%, touching an intraday low of Rs.123.15, which also represents the stock’s all-time low. This decline outpaced the hospital sector’s performance, underperforming by approximately -1.4% on the day. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market index, Sensex, opened lower at 83,252.06 points, down by -487.07 points (-0.58%), but has since recovered slightly to trade near 83,672.18 points (-0.08%). The Sensex remains within 2.97% of its 52-week high of 86,159.02, indicating relative resilience in the broader market despite the pressure on GPT Healthcare’s shares.
Long-Term and Recent Performance Trends
GPT Healthcare Ltd’s stock has experienced a notable decline over the past year, delivering a negative return of -24.49%, significantly lagging behind the Sensex’s positive 6.47% gain over the same period. The stock’s 52-week high was Rs.184.80, highlighting the extent of the recent depreciation. Over the last three years, the company has also underperformed the BSE500 index, reflecting persistent challenges in maintaining growth and investor confidence.
These trends have contributed to a downgrade in the company’s Mojo Grade from Hold to Sell as of 30 September 2025, with a current Mojo Score of 36.0. The Market Cap Grade stands at 3, indicating a moderate market capitalisation relative to peers.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Financial Performance and Profitability Metrics
GPT Healthcare Ltd has reported negative results for three consecutive quarters, reflecting pressure on its earnings. Operating profit has declined at an annualised rate of -10.80% over the past five years, indicating subdued long-term growth. The company’s interest expense has increased significantly, rising by 66.79% over the last six months to Rs.4.42 crores, which has impacted profitability.
The operating profit to interest coverage ratio has fallen to a low of 9.16 times, signalling tighter margins for servicing debt. Return on Capital Employed (ROCE) for the half-year period stands at 18.76%, which, while positive, is the lowest recorded in recent periods. These factors have contributed to the stock’s current Sell rating.
Institutional Investor Participation
Institutional investors have reduced their holdings by -0.72% in the previous quarter, now collectively holding 8.94% of the company’s shares. This decline in institutional participation may reflect a reassessment of the company’s fundamentals by investors with greater analytical resources, potentially influencing market sentiment.
Valuation and Debt Position
Despite the recent price decline, GPT Healthcare Ltd maintains a relatively attractive valuation. The company’s ROCE of 18.7% and a low Debt to EBITDA ratio of 0.53 times indicate efficient capital utilisation and a strong ability to service debt obligations. The enterprise value to capital employed ratio stands at 3.5, suggesting the stock is trading at a discount compared to its peers’ historical valuations.
However, the company’s profits have fallen by -18.7% over the past year, which aligns with the stock’s negative return of -24.49% during the same period. This correlation underscores the challenges faced in maintaining earnings growth amid a competitive hospital sector environment.
Holding GPT Healthcare Ltd from Hospital? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Management Efficiency and Operational Strengths
GPT Healthcare Ltd demonstrates high management efficiency, reflected in a strong ROCE of 25.62% in certain periods. This suggests effective utilisation of capital resources despite the broader challenges faced by the company. The low leverage, as indicated by the Debt to EBITDA ratio, further supports the company’s capacity to manage its financial obligations prudently.
Nevertheless, these strengths have not been sufficient to offset the downward pressure on the stock price, which remains at its lowest level in over a year.
Summary of Key Metrics
To summarise, GPT Healthcare Ltd’s stock performance and financial indicators as of early February 2026 are as follows:
- New 52-week and all-time low price: Rs.123.15
- One-year stock return: -24.49%
- Five-year annualised operating profit growth: -10.80%
- Interest expense growth (last six months): 66.79% to Rs.4.42 crores
- Operating profit to interest coverage ratio: 9.16 times (lowest)
- ROCE (half-year): 18.76%
- Debt to EBITDA ratio: 0.53 times
- Enterprise value to capital employed: 3.5
- Institutional investor holding: 8.94%, down -0.72% from previous quarter
- Mojo Score: 36.0 (Sell), downgraded from Hold on 30 September 2025
These figures illustrate the stock’s current valuation and performance challenges within the hospital sector, set against a backdrop of broader market stability.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
